Literature DB >> 2543478

Inclusion body myositis. Observations in 40 patients.

B P Lotz1, A G Engel, H Nishino, J C Stevens, W J Litchy.   

Abstract

Inclusion body myositis (IBM) was suspected on light microscopic grounds in 48 of 170 consecutive patients with inflammatory myopathies. One or more vacuoles containing membranous material, groups of atrophic fibres, and an autoaggressive endomysial inflammatory exudate occurred in 100, 96 and 92% of the muscle specimens. All three of these features were present in 88% of the specimens. Electron microscopy confirmed the presence of filamentous inclusions in 40 of 43 patients. The inclusions are typically near vacuoles and a minimum of three vacuolated fibres must be scrutinized to detect them with confidence. There is no electromyographic pattern that can reliably distinguish IBM from other inflammatory myopathies. The typical clinical features in the patients diagnosed by histological criteria as IBM were: insidious onset after age 50 yrs with painless, proximal lower extremity weakness; slow but relentless progression with selectively severe involvement of quadriceps, iliopsoas, tibialis anterior, biceps and triceps muscles; relatively early depression of the knee reflexes; and a normal or mildly elevated serum creatine kinase level. The male: female ratio was 3:1. Distal weakness occurred in about 50%, but only in 35% was it as great or greater than proximal weakness. Significant associated illnesses include other autoimmune disorders (15%), diabetes mellitus (20%), and diffuse peripheral neuropathy (18%). Prednisone treatment at dose levels frequently effective in polymyositis failed to prevent disease progression in those patients observed for 2 or more years. Our findings support the notion that IBM is a distinct entity in which a set of pathological features is associated with a constellation of clinical findings.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543478     DOI: 10.1093/brain/112.3.727

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  61 in total

1.  Fast and reliable new method for electron-microscopic identification of cytoplasmic tubulo-filaments in muscle biopsies of patients with inclusion-body myositis.

Authors:  V Askanas; R B Alvarez
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 2.  Polymyositis/dermatomyositis: the current position.

Authors:  A Urbano-Márquez; J Casademont; J M Grau
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

Review 3.  The idiopathic inflammatory myopathies and their treatment.

Authors:  J Walton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

4.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

5.  Intranuclear and cytoplasmic filamentous inclusions in distal myopathy (Welander).

Authors:  K Borg; F M Tomé; L Edström
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

6.  A case of inclusion body myositis responsive to prednisolone therapy.

Authors:  Rahul Kalla; Majella Soumakiyan; Stephen Tuck
Journal:  Clin Rheumatol       Date:  2008-12-06       Impact factor: 2.980

7.  When myopathy strikes in a cancer patient.

Authors:  Srivalli Gopaluni; Lilian M Thomas; Chirag Shah
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.

Authors:  V Askanas; W K Engel; M Bilak; R B Alvarez; D J Selkoe
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

9.  Formation of gelsolin amyloid fibrils in the rough endoplasmic reticulum of skeletal muscle in the gelsolin mouse model of inclusion body myositis: comparative analysis to human sporadic inclusion body myositis.

Authors:  Sergei I Bannykh; William E Balch; Jeffery W Kelly; Lesley J Page; G Diane Shelton
Journal:  Ultrastruct Pathol       Date:  2013-10       Impact factor: 1.094

Review 10.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.